Skip to main content
Top
Published in: Gastric Cancer 1/2017

01-03-2017 | Original Article

Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma

Authors: Hiroharu Yamashita, Yasuyuki Seto, Takeshi Sano, Hiroyasu Makuuchi, Nobutoshi Ando, Mitsuru Sasako, On behalf of the Japanese Gastric Cancer Association and the Japan Esophageal Society

Published in: Gastric Cancer | Special Issue 1/2017

Login to get access

Abstract

Background

Esophagogastric junction (EGJ) carcinoma has attracted considerable attention because of the marked increase in its incidence globally. However, the optimal extent of esophagogastric resection for this tumor entity remains highly controversial.

Methods

This was a questionnaire-based national retrospective study undertaken in an attempt to define the optimal extent of lymph node dissection for EGJ cancer. Data from patients with EGJ carcinoma, less than 40 mm in diameter, who underwent R0 resection between January 2001 and December 2010 were reviewed.

Results

Clinical records of 2807 patients without preoperative therapy were included in the analysis. There are distinct disparities in terms of the nodal dissection rate according to histology and the predominant tumor location. Nodal metastases frequently involved the abdominal nodes, especially those at the right and left cardia, lesser curvature and along the left gastric artery. Nodes along the distal portion of the stomach were much less often metastatic, and their dissection seemed unlikely to be beneficial. Lower mediastinal node dissection might contribute to improving survival for patients with esophagus-predominant EGJ cancer. However, due to low dissection rates for nodes of the middle and upper mediastinum, no conclusive result was obtained regarding the optimal extent of nodal dissection in this region.

Conclusions

Complete nodal clearance along the distal portion of the stomach offers marginal survival benefits for patients with EGJ cancers less than 4 cm in diameter. The optimal extent of esophageal resection and the benefits of mediastinal node dissection remain issues to be addressed in managing patients with esophagus-predominant EGJ cancers.
Literature
1.
go back to reference Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–7.CrossRefPubMedPubMedCentral Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184–7.CrossRefPubMedPubMedCentral
2.
go back to reference Dikken JL, Lemmens VE, Wouters MW, Wijnhoven BP, Siersema PD, Nieuwenhuijzen GA, et al. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer. 2012;48:1624–32.CrossRefPubMed Dikken JL, Lemmens VE, Wouters MW, Wijnhoven BP, Siersema PD, Nieuwenhuijzen GA, et al. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer. 2012;48:1624–32.CrossRefPubMed
3.
go back to reference Miyazaki T, Inose T, Tanaka N, Yokobori T, Suzuki S, Ozawa D, et al. Management of Barrett’s esophageal carcinoma. Surg Today. 2013;43:353–60.CrossRefPubMed Miyazaki T, Inose T, Tanaka N, Yokobori T, Suzuki S, Ozawa D, et al. Management of Barrett’s esophageal carcinoma. Surg Today. 2013;43:353–60.CrossRefPubMed
4.
go back to reference Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330–44.CrossRefPubMed Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330–44.CrossRefPubMed
5.
go back to reference Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23:1662–5.CrossRefPubMed Kusano C, Gotoda T, Khor CJ, Katai H, Kato H, Taniguchi H, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23:1662–5.CrossRefPubMed
6.
go back to reference Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011;12:296–305.CrossRefPubMed Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011;12:296–305.CrossRefPubMed
7.
go back to reference Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–112. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–112.
8.
go back to reference Ajani JA, Barthel JS, Bentrem DJ, D’Amico TA, Das P, Denlinger CS, et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011;9:830–87.PubMed Ajani JA, Barthel JS, Bentrem DJ, D’Amico TA, Das P, Denlinger CS, et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011;9:830–87.PubMed
9.
go back to reference Society JE. Japanese classification of esophageal cancer, 2nd English edition. Tokyo, Kanehara. Society JE. Japanese classification of esophageal cancer, 2nd English edition. Tokyo, Kanehara.
10.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind CH. TNM Classification of Malignant TumoursWiley-Blackwell. Sobin LH, Gospodarowicz MK, Wittekind CH. TNM Classification of Malignant TumoursWiley-Blackwell.
11.
go back to reference Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.CrossRefPubMed Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.CrossRefPubMed
12.
go back to reference Ozawa S, Tachimori Y, Baba H, Matsubara H, Muro K, Numasaki H, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2001. Esophagus. 2009;6:95–110.CrossRef Ozawa S, Tachimori Y, Baba H, Matsubara H, Muro K, Numasaki H, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2001. Esophagus. 2009;6:95–110.CrossRef
13.
go back to reference Tachimori Y, Ozawa S, Fujishiro M, Matsubara H, Numasaki H, Oyama T, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2005. Esophagus. 2014;11:1–20.CrossRef Tachimori Y, Ozawa S, Fujishiro M, Matsubara H, Numasaki H, Oyama T, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2005. Esophagus. 2014;11:1–20.CrossRef
14.
go back to reference Tachimori Y, Ozawa S, Numasaki H, Fujishiro M, Matsubara H, Oyama T, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus. 2016;13:110–37.CrossRefPubMedPubMedCentral Tachimori Y, Ozawa S, Numasaki H, Fujishiro M, Matsubara H, Oyama T, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus. 2016;13:110–37.CrossRefPubMedPubMedCentral
15.
go back to reference Yabusaki H, Nashimoto A, Matsuki A, Aizawa M. Comparison of the surgical treatment strategies for Siewert type II squamous cell carcinoma in the same area as esophagogastric junction carcinoma: data from a single Japanese high-volume cancer center. Surg Today. 2014;44:1522–8.CrossRefPubMed Yabusaki H, Nashimoto A, Matsuki A, Aizawa M. Comparison of the surgical treatment strategies for Siewert type II squamous cell carcinoma in the same area as esophagogastric junction carcinoma: data from a single Japanese high-volume cancer center. Surg Today. 2014;44:1522–8.CrossRefPubMed
16.
go back to reference Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254:274–80.CrossRefPubMed Yamashita H, Katai H, Morita S, Saka M, Taniguchi H, Fukagawa T. Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg. 2011;254:274–80.CrossRefPubMed
17.
go back to reference Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol. 2012;19:677–83.CrossRefPubMed Hosokawa Y, Kinoshita T, Konishi M, Takahashi S, Gotohda N, Kato Y, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol. 2012;19:677–83.CrossRefPubMed
18.
go back to reference Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg. 2013;100:261–6.CrossRefPubMed Mine S, Sano T, Hiki N, Yamada K, Nunobe S, Yamaguchi T. Lymphadenectomy around the left renal vein in Siewert type II adenocarcinoma of the oesophagogastric junction. Br J Surg. 2013;100:261–6.CrossRefPubMed
19.
go back to reference Yoshikawa T, Takeuchi H, Hasegawa S, Nozaki I, Kishi K, Ito S, et al. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. Gastric Cancer. 2016;19:143–9.CrossRefPubMed Yoshikawa T, Takeuchi H, Hasegawa S, Nozaki I, Kishi K, Ito S, et al. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction. Gastric Cancer. 2016;19:143–9.CrossRefPubMed
20.
go back to reference Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353–61.CrossRef Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000;232:353–61.CrossRef
21.
go back to reference Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, et al. Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg. 2008;32:1013–20.CrossRefPubMed Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, et al. Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg. 2008;32:1013–20.CrossRefPubMed
22.
go back to reference Takeuchi H, Fujii H, Ando N, Ozawa S, Saikawa Y, Suda K, et al. Validation study of radio-guided sentinel lymph node navigation in esophageal cancer. Ann Surg. 2009;249:757–63.CrossRefPubMed Takeuchi H, Fujii H, Ando N, Ozawa S, Saikawa Y, Suda K, et al. Validation study of radio-guided sentinel lymph node navigation in esophageal cancer. Ann Surg. 2009;249:757–63.CrossRefPubMed
23.
go back to reference Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2016. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2016.
24.
go back to reference Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979–85.CrossRefPubMed Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979–85.CrossRefPubMed
25.
go back to reference van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed
26.
go back to reference Fujitani K, Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, et al. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study. Gastric Cancer. 2013;16:301–8.CrossRefPubMed Fujitani K, Miyashiro I, Mikata S, Tamura S, Imamura H, Hara J, et al. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia: results of a multicenter study. Gastric Cancer. 2013;16:301–8.CrossRefPubMed
27.
go back to reference Matsuda T, Kurokawa Y, Yoshikawa T, Kishi K, Misawa K, Ohi M, et al. Clinicopathological characteristics and prognostic factors of patients with siewert type II esophagogastric junction carcinoma: a retrospective multicenter study. World J Surg. 2016;40:1672–9.CrossRefPubMed Matsuda T, Kurokawa Y, Yoshikawa T, Kishi K, Misawa K, Ohi M, et al. Clinicopathological characteristics and prognostic factors of patients with siewert type II esophagogastric junction carcinoma: a retrospective multicenter study. World J Surg. 2016;40:1672–9.CrossRefPubMed
28.
go back to reference Aikou T, Shimazu H. Difference in main lymphatic pathways from the lower esophagus and gastric cardia. Jpn J Surg. 1989;19:290–5.CrossRefPubMed Aikou T, Shimazu H. Difference in main lymphatic pathways from the lower esophagus and gastric cardia. Jpn J Surg. 1989;19:290–5.CrossRefPubMed
29.
go back to reference Rice TW, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg. 1998;65:787–92.CrossRefPubMed Rice TW, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg. 1998;65:787–92.CrossRefPubMed
30.
go back to reference Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer, Epub ahead of print. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer, Epub ahead of print.
Metadata
Title
Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma
Authors
Hiroharu Yamashita
Yasuyuki Seto
Takeshi Sano
Hiroyasu Makuuchi
Nobutoshi Ando
Mitsuru Sasako
On behalf of the Japanese Gastric Cancer Association and the Japan Esophageal Society
Publication date
01-03-2017
Publisher
Springer Japan
Published in
Gastric Cancer / Issue Special Issue 1/2017
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-016-0663-8

Other articles of this Special Issue 1/2017

Gastric Cancer 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.